Last updated: September 2, 2026
Ziv-aflibercept, marketed as Zaltrap by Sanofi and Regeneron, is a mature oncology biologic with declining commercial relevance. Its value is constrained by a narrow indication, intensive intravenous administration, competition from lower-cost chemotherapy regimens, and the loss of core patent protection. Revenue peaked shortly after its 2012 launch and subsequently declined as hospitals resisted its price, treatment adoption remained limited, and the colorectal cancer market shifted toward targeted and biomarker-driven therapies.
What is ziv-aflibercept and how is it used?
Ziv-aflibercept is a recombinant fusion protein that binds vascular endothelial growth factor A, VEGF-B, and placental growth factor. It inhibits tumor angiogenesis by acting as a soluble VEGF receptor decoy.
The FDA approved Zaltrap on August 3, 2012, for use with FOLFIRI, consisting of irinotecan, fluorouracil, and leucovorin, in adults with metastatic colorectal cancer whose disease has progressed during or after an oxaliplatin-containing regimen. The approved dose is 4 mg/kg by intravenous infusion every two weeks, administered before the FOLFIRI regimen.[1]
The approval was based primarily on the VELOUR trial:
| Metric |
FOLFIRI plus ziv-aflibercept |
FOLFIRI plus placebo |
| Median overall survival |
13.5 months |
12.06 months |
| Overall-survival hazard ratio |
0.817 |
Reference |
| Median progression-free survival |
6.9 months |
4.67 months |
| Objective response rate |
19.8% |
11.1% |
The clinical benefit was statistically significant but accompanied by substantial toxicity, including neutropenia, diarrhea, stomatitis, hypertension, hemorrhage, and proteinuria. The safety burden limits use in patients with poor performance status or significant comorbidities.[1]
How large is the ziv-aflibercept market?
The addressable market is narrower than the broader colorectal cancer market because Zaltrap is used only after progression on an oxaliplatin-containing regimen and is generally administered with FOLFIRI. It competes within a heavily treated, price-sensitive segment rather than serving as a foundational first-line therapy.
Main demand drivers
Demand is determined by:
- The number of patients reaching second-line or later-line metastatic colorectal cancer treatment.
- Physician willingness to add a costly biologic to FOLFIRI.
- Reimbursement policies and hospital formulary decisions.
- Availability of alternative anti-VEGF and anti-EGFR therapies.
- Patient molecular profile, including RAS and BRAF status.
- The toxicity profile and performance status of the patient population.
Ziv-aflibercept does not have a biomarker-defined population. That broadens theoretical eligibility but weakens differentiation because clinicians can choose among several biologic and targeted options.
Principal competing therapies
| Therapy |
Main mechanism |
Typical commercial position |
| Bevacizumab |
Anti-VEGF-A antibody |
Broad colorectal cancer use, now exposed to biosimilar competition |
| Ziv-aflibercept |
VEGF-trap fusion protein |
Later-line FOLFIRI combination |
| Ramucirumab |
VEGFR2 antibody |
Later-line FOLFIRI combination |
| Cetuximab |
EGFR antibody |
RAS wild-type disease, often selected by molecular profile |
| Panitumumab |
EGFR antibody |
RAS wild-type disease |
| Trifluridine/tipiracil |
Oral cytotoxic combination |
Later-line therapy |
| Regorafenib |
Oral multikinase inhibitor |
Later-line therapy |
Bevacizumab is the most important commercial comparator because it is familiar to oncologists, available in biosimilar form, and used across multiple lines of colorectal cancer treatment. Ziv-aflibercept therefore requires a meaningful clinical or economic advantage to displace established anti-VEGF therapy.
Why did Zaltrap sales weaken after launch?
The initial US launch created a pricing controversy. The wholesale acquisition cost was approximately $11,000 per dose, implying an estimated monthly drug cost of more than $10,000 for a typical patient before discounts and administration costs. Memorial Sloan Kettering Cancer Center publicly excluded the product from its formulary because the clinical benefit was viewed as insufficient relative to its price.[2]
Sanofi subsequently reduced the effective price by approximately 50% through discounts and patient-support measures. The intervention protected access but reduced revenue per treated patient and weakened the product's premium positioning.
The commercial trajectory followed four phases:
| Period |
Market phase |
Financial effect |
| 2012-2013 |
Launch and rapid formulary scrutiny |
Strong initial visibility, but limited uptake at list price |
| 2014-2016 |
Discount-led access strategy |
Higher price concessions and lower realized revenue per patient |
| 2017-2020 |
Mature-line competition |
Declining utilization and reduced strategic priority |
| 2021 onward |
Post-core-patent maturity |
Limited growth, generic and biosimilar attention, low standalone relevance |
Sanofi and Regeneron did not develop Zaltrap into a broad immuno-oncology platform. The product remained tied to one principal indication, reducing its ability to offset loss of exclusivity or changing treatment standards.
What is the financial trajectory of ziv-aflibercept?
Zaltrap generated commercial revenue after launch but did not become a major growth product for either partner. Sanofi reported the product as part of its oncology portfolio and, in later reporting periods, provided less standalone financial detail as sales declined and the product became less material to group performance.[3]
Regeneron's economics were based on its collaboration with Sanofi. Regeneron generally received collaboration-related revenue rather than treating Zaltrap as a fully independent commercial franchise. The financial contribution was materially smaller than Regeneron's major ophthalmology and immunology products, including Eylea and Dupixent.[4]
Financial characteristics
The product's revenue profile has four defining characteristics:
- Low market expansion potential. The label is concentrated in previously treated metastatic colorectal cancer.
- High discount sensitivity. Hospital buyers exert significant pressure on biologic oncology pricing.
- Limited lifecycle optionality. There has been no major new indication or differentiated formulation.
- Declining reporting importance. The product is no longer a central driver of Sanofi's or Regeneron's earnings disclosures.
A reasonable commercial assessment is that ziv-aflibercept is now a declining, mature revenue stream rather than a growth asset. Its remaining value lies in cash generation from established demand, manufacturing continuity, and potential defensive contracting, not in substantial market expansion.
When does ziv-aflibercept lose exclusivity?
The core composition-of-matter patent estate associated with the VEGF-trap technology reached the end of its principal US term in the early 2020s. Public patent records identify the foundational VEGF-antagonist patent family, including US Patent No. 7,374,757, as having an expiration date in 2022, subject to applicable patent-term adjustments and extensions.[5]
Later patents and related claims may cover specific formulations, manufacturing processes, dosing regimens, or therapeutic uses. Those patents do not necessarily create a commercially effective barrier if they do not cover the product broadly or if a competing manufacturer can design around them.
The relevant exclusivity distinction is:
| Protection type |
Status and commercial effect |
| FDA regulatory exclusivity |
The original 12-year biologic exclusivity period has expired |
| Core composition patent |
Principal US protection expired in the early 2020s |
| Method-of-use patents |
May remain relevant for specific treatment claims |
| Formulation patents |
Potentially relevant, but narrower than composition claims |
| Manufacturing patents |
Can delay entry if technically difficult to design around |
| Pediatric exclusivity |
No major commercial extension is associated with Zaltrap's principal US franchise |
Ziv-aflibercept is a biologic, so a competitor would generally pursue a biosimilar or a separate biologics license rather than a conventional ANDA for a small-molecule generic.
What is the FDA and Orange Book status of Zaltrap?
Zaltrap was approved under a biologics license application, BLA 125418. It is not a conventional small-molecule NDA product. The relevant regulatory record is therefore the FDA biologics database and the Purple Book framework, not the standard Orange Book patent-listing structure used for most NDA products.[1,6]
This distinction affects market entry:
- A conventional ANDA pathway is not the normal route for ziv-aflibercept.
- A biosimilar applicant would need to demonstrate biosimilarity under the Public Health Service Act.
- Interchangeability would require a separate FDA determination.
- Patent disputes would be governed primarily by the Biologics Price Competition and Innovation Act, including patent-exchange procedures and potential federal litigation.
- The presence of an aflibercept biosimilar for ophthalmic use would not automatically authorize substitution for Zaltrap in oncology.
Are there biosimilar or generic risks for ziv-aflibercept?
Direct biosimilar risk is real but commercially difficult. Ziv-aflibercept is a complex fusion protein requiring control of molecular size, glycosylation, aggregation, potency, impurities, and stability. A biosimilar manufacturer must also validate a reliable large-scale cell-culture and purification process.
Why entry may be slower than patent expiry suggests
Patent expiry does not guarantee rapid competition because:
- The oncology market is smaller than the ophthalmic aflibercept market.
- Zaltrap and Eylea have different approved uses, formulations, concentrations, and delivery settings.
- A manufacturer may prioritize an aflibercept product for ophthalmology, where market demand is substantially larger.
- Oncology procurement is concentrated among hospitals and group purchasing organizations.
- The reference product's declining sales may not justify the cost of a dedicated biosimilar program.
- Clinical development, comparability testing, manufacturing validation, and regulatory filing costs remain significant.
The strongest competitive risk may come from manufacturers using aflibercept-related manufacturing know-how for an oncology product, rather than from a conventional generic launch.
What patent litigation and Paragraph IV challenges affect Zaltrap?
Zaltrap does not have the same conventional Paragraph IV litigation profile as a small-molecule product listed in the Orange Book. A biosimilar or competing biologic would generally trigger the BPCIA patent process rather than a standard ANDA Paragraph IV certification.
The litigation risk is concentrated in four areas:
Composition and sequence claims
These claims are the strongest form of protection because they can cover the active fusion protein broadly. The principal early patent protection has expired or substantially weakened.
Formulation claims
Formulation patents may address concentration, buffer systems, osmolarity, stability, or excipient combinations. Their value depends on whether the competing product can use a non-infringing formulation while maintaining comparable clinical performance.
Method-of-use claims
Claims covering ziv-aflibercept with FOLFIRI in metastatic colorectal cancer can support litigation, but their practical value is limited if competitors receive a label that omits the patented indication or rely on physician prescribing practices outside the labeled use.
Manufacturing claims
Manufacturing patents can be more important than formulation patents for biologics because cell lines, purification sequences, and process conditions affect product quality. They can create delay even after broad composition patents expire.
No major public US biosimilar litigation campaign has established a direct market-blocking threat to Zaltrap comparable to the high-profile Eylea patent disputes. The current risk is best characterized as potential entry pressure rather than an active, proven launch event.
How does ziv-aflibercept compare with Eylea?
Ziv-aflibercept and aflibercept are closely related VEGF-trap molecules, but they are commercialized in different products and indications.
| Attribute |
Zaltrap |
Eylea |
| Active biologic |
Ziv-aflibercept |
Aflibercept |
| Primary indication |
Metastatic colorectal cancer |
Retinal vascular and macular diseases |
| Administration |
Intravenous with FOLFIRI |
Intravitreal injection |
| Commercial market |
Oncology |
Ophthalmology |
| Market scale |
Narrower |
Substantially larger |
| Biosimilar incentive |
Moderate to low |
High |
| Principal commercial sponsor |
Sanofi and Regeneron |
Regeneron and Bayer outside the US |
The larger Eylea market has attracted greater patent, biosimilar, and manufacturing attention. A biosimilar developed for ophthalmology does not automatically create a substitutable oncology product for Zaltrap. Regulatory approval, formulation, presentation, and labeling remain separate issues.
What generic launch scenarios exist for ziv-aflibercept?
Three entry scenarios are commercially credible.
Scenario 1: No near-term direct biosimilar
This is the most conservative scenario. The market continues to decline gradually, with Sanofi retaining residual demand through contracting, physician familiarity, and supply continuity.
Scenario 2: Limited oncology biosimilar entry
One or more manufacturers launch a ziv-aflibercept biosimilar after completing a 351(k) program or obtaining a separate BLA. Price erosion would likely be significant because hospital purchasers can shift volume rapidly once multiple suppliers qualify.
Scenario 3: Cross-market aflibercept manufacturing entry
A manufacturer enters the larger ophthalmic aflibercept market and later applies related manufacturing capability to an oncology presentation. This would increase long-term competitive risk, although the clinical, formulation, and regulatory requirements would remain distinct.
Under any entry scenario, a first competitor would likely receive the largest price advantage. Additional entrants would intensify tendering and compress margins further.
How strong is the ziv-aflibercept patent estate?
The estate is weak for long-term exclusivity and moderate for short-term litigation leverage.
| Dimension |
Assessment |
| Broad composition protection |
Weak after expiry of foundational patents |
| Regulatory exclusivity |
Expired |
| Formulation protection |
Potentially moderate, but narrow |
| Method-of-use protection |
Moderate for labeled FOLFIRI use |
| Manufacturing protection |
Potentially meaningful |
| Biosimilar litigation leverage |
Lower than for actively protected biologics |
| Commercial differentiation |
Weak |
| Long-term revenue defense |
Low |
The principal weakness is the absence of a broad, unexpired composition patent that clearly controls all economically viable products. The principal residual strength is process complexity combined with a small, established oncology customer base.
What licensing deals govern ziv-aflibercept?
Zaltrap was developed through the Sanofi-Regeneron collaboration. Regeneron contributed its VEGF-trap technology and development expertise, while Sanofi led substantial commercialization activities, particularly outside the United States. The relationship formed part of a broader strategic alliance between the companies rather than a stand-alone licensing arrangement limited only to Zaltrap.[4]
The collaboration is commercially important because it affects:
- Revenue sharing between Sanofi and Regeneron.
- Control of global commercialization.
- Manufacturing and supply responsibilities.
- Development decisions for new indications.
- The allocation of legal and patent costs.
The product's declining revenue reduces its strategic leverage within that alliance. It is unlikely to influence the partners' capital allocation as strongly as Regeneron's major growth products.
What is the investment outlook for ziv-aflibercept?
Ziv-aflibercept is a harvesting asset, not a growth asset. Its financial profile is characterized by:
- Declining demand in a mature indication.
- Low probability of substantial label expansion.
- Increasing exposure to biosimilar and biologic competition.
- Limited pricing power after the original launch controversy.
- Potential margin pressure from hospital contracting.
- Minimal relevance to the overall earnings outlook of Sanofi or Regeneron.
Revenue exposure remains more material to the product's operating units than to consolidated corporate results. A successful biosimilar launch could accelerate erosion, but the absolute financial effect on either parent company would likely be limited compared with major products such as Dupixent, Eylea, or other large oncology franchises.
Key Takeaways
- Ziv-aflibercept is a mature biologic for previously treated metastatic colorectal cancer.
- Its principal commercial use is in combination with FOLFIRI.
- The VELOUR trial demonstrated a modest overall-survival benefit with considerable toxicity.
- The 2012 US price triggered hospital and payer resistance, forcing major discounting.
- Core patent protection weakened materially after 2022.
- Zaltrap is regulated as a biologic and is not a conventional Orange Book small-molecule product.
- Direct biosimilar risk exists but is constrained by the limited oncology market and manufacturing complexity.
- Eylea-related aflibercept competition does not automatically create a substitutable Zaltrap product.
- Sanofi and Regeneron now treat the product as a mature, declining revenue stream.
- The strongest remaining barriers are manufacturing know-how, formulation controls, and hospital procurement relationships.
FAQs
Is ziv-aflibercept the same drug as Eylea?
They are closely related VEGF-trap biologics, but Zaltrap and Eylea are separate commercial products with different indications, formulations, concentrations, routes of administration, and regulatory approvals.
Can a generic manufacturer file an ANDA for Zaltrap?
A conventional ANDA is generally not the appropriate pathway because Zaltrap is a biologic. A competing manufacturer would more likely pursue a 351(k) biosimilar application or a separate biologics license application.
Does Zaltrap have current Orange Book patent protection?
Zaltrap is principally regulated through the biologics framework. Its patent and regulatory position should be evaluated through FDA biologics records, Purple Book information, BPCIA procedures, and public patent databases rather than relying solely on Orange Book listings.
What is the main clinical alternative to ziv-aflibercept?
Bevacizumab-based FOLFIRI is the closest broad anti-VEGF alternative. Ramucirumab plus FOLFIRI is another later-line option, while cetuximab or panitumumab may be preferred for molecularly selected RAS wild-type patients.
Could a Zaltrap biosimilar materially reduce treatment costs?
Yes. Hospital and group-purchasing contracts could produce meaningful price erosion if a qualified biosimilar enters. The reduction would depend on the number of entrants, interchangeability status, supply reliability, and payer adoption.
References
- U.S. Food and Drug Administration. (2012). Zaltrap (ziv-aflibercept) prescribing information.
- Bach, P. B. (2013). Limits on Medicare’s ability to control rising spending on cancer drugs. New England Journal of Medicine, 368(7), 626-633.
- Sanofi. (2013-2023). Annual reports and universal registration documents.
- Regeneron Pharmaceuticals, Inc. (2012-2023). Annual reports and Form 10-K filings.
- United States Patent and Trademark Office. (2024). Patent records for VEGF antagonist and VEGF-trap patent families.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
